CSBR

Champions Oncology Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$84.24M
P/E Ratio
EPS
$-0.18
Beta
0.39
52W High
$8.98
52W Low
$5.50
50-Day MA
$6.05
200-Day MA
$6.35
Dividend Yield
Profit Margin
-4.04%
Forward P/E
22.88
PEG Ratio
0.00

About Champions Oncology Inc

Champions Oncology, Inc. develops and sells technology products and solutions to customize the development and use of cancer drugs in the United States. The company is headquartered in Hackensack, New Jersey.

Official WebsiteUSAFY End: April

Fundamentals

Revenue (TTM)$57.95M
Gross Profit (TTM)$26.58M
EBITDA-772,000
Operating Margin-1.13%
Return on Equity-47.60%
Return on Assets-4.70%
Revenue/Share (TTM)$4.20
Book Value$0.31
Price-to-Book18.68
Price-to-Sales (TTM)1.45
EV/Revenue1.342
EV/EBITDA20.48
Quarterly Earnings Growth (YoY)-61.10%
Quarterly Revenue Growth (YoY)-2.80%
Shares Outstanding$13.89M
Float$6.07M
% Insiders26.67%
% Institutions41.38%

Historical Volatility

HV 10-Day
63.59%
HV 20-Day
74.53%
HV 30-Day
61.49%
HV 60-Day
51.21%
HV Rank
57.1%

Volatility is currently expanding

Latest News

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions HACKENSACK, NJ / ACCESS Newswire / April 9, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced it will present new data across eight poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, California. The presentations will highlight research across key areas of oncology drug development, including KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, antibody-drug conjugates (ADCs), and CAR-T therapies.

Accesswire4/9/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026